Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda) and targeted therapies (e.g., Eisai’s Lenvima) are experiencing uptake. Some agents target specific biomarker-defined populations, such as MSI-H or dMMR, and others target all patients. The approval and uptake of these agents will result in a more-personalized approach to treating advanced endometrial carcinoma. Several agents are also being positioned for the untapped first-line setting (e.g., GSK/Tesaro’s dostarlimab, Karyopharm’s Xpovio, AstraZeneca’s Lynparza) and will contribute to robust market growth over the 2019-2029 forecast period.
Questions Answered
- How large are the clinically and commercially relevant drug-treatable endometrial carcinoma populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Keytruda and Lenvima, for endometrial carcinoma?
- Which pipeline products are poised to become options for the treatment of endometrial carcinoma, and what sales / uptake will they secure?
- What are the key drivers and constraints in the endometrial carcinoma market, and how will the major markets evolve over the ten-year forecast period?
Content Highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists.
Epidemiology: Diagnosed incident of endometrial carcinoma by country, disease stage, and risk status.
Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key endometrial cancer therapies through 2029, segmented by brands / biosimilars / generics, disease stage, and country.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select early-phase products.
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Endometrial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Key Findings
- Market Outlook
- Key Findings
- Major-Market Share of Drug Classes for Endometrial Carcinoma: 2019
- Major-Market Share of Drug Classes for Endometrial Carcinoma: 2029
- Major-Market Sales of Key Therapies for Endometrial Carcinoma: 2019-2029
- Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2019
- Drug-Treatable Population Share and Major-Market Sales Share in Endometrial Carcinoma: 2029
- Positioning of Key Therapies in Endometrial Carcinoma in the United States: 2019-2029
- Population Positioning of Therapies in Endometrial Carcinoma
- SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- Segment-Specific Trends
- Key Findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key Findings
- Treatment Goals
- Key Current Therapies
- Medical Practice
- Newly Diagnosed Early-Stage (Stage I-II) Endometrial Carcinoma
- First-Line Advanced or Recurrent Endometrial Carcinoma
- Second- and Later-Line Advanced or Metastatic Endometrial Carcinoma
- Country-Specific Endometrial Carcinoma Treatment Guidelines
- Patient Characteristics Influencing Drug Selection in Endometrial Carcinoma
- Region-Specific Treatment Practices
- Key Findings
- Unmet Need Overview
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.